Merck's Latest Inspiration Is Bolt-On Acquisition of Inspire Pharma for $430M
This article was originally published in The Pink Sheet Daily
Executive Summary
The troubled specialty pharma offers Merck immediate revenues in ophthalmology, while the Big Pharma waits for approval of a new drug, Saflutan, for glaucoma and ocular hypertension.